Gilead Sciences (GILD) stock was down by 2.15% due to competitive pressure from other biotech firms such as Assembly Biosciences and Targeted Medical Pharma, which may have raised concerns among investors about Gilead's market position and growth potential.

Gilead Sciences (GILD) stock was down by 2

Gilead Sciences (GILD) stock declined by 2.15% as it reacted negatively to broader market trends and uncertainty surrounding future earnings, despite significant investments from Orchestra BioMed and Medtronic aimed at advancing their cardiology programs, indicating a lack of investor confidence in Gilead's immediate outlook.

Gilead Sciences (GILD) stock declined by 2

Gilead Sciences (GILD) stock fell by 2.15% due to broader market trends and investor sentiment potentially influenced by recent news, including significant IPOs like Figma's, which may be diverting focus and capital away from established biotech stocks like Gilead.

Gilead Sciences (GILD) stock fell by 2

Gilead Sciences (GILD) stock rose by 0.46% due to increased institutional investment, including a significant new position acquired by Gilead in Leap Therapeutics, suggesting positive market sentiment towards its strategic investments and growth potential in biotechnology.

Gilead Sciences (GILD) stock rose by 0

The Gilead Sciences (GILD) stock rose by 1.06% as analysts at Leerink Partners upgraded their earnings estimates for Galapagos NV, a biotechnology company in which Gilead has invested significantly, reflecting increased investor confidence in the company's financial outlook and potential growth.

The Gilead Sciences (GILD) stock rose by 1

Gilead Sciences (GILD) stock fell by 2.73% amidst general volatility in the pharmaceutical sector, which is often influenced by news regarding clinical trials, drug approvals, and market trends, although specific reasons for Gilead's decline were not detailed in the article.

Gilead Sciences (GILD) stock declined by 2.73% despite recent upgrades and positive analyst ratings due to lower-than-expected revenue in its last quarterly earnings report and insider stock sales that may indicate waning confidence among executives.

Gilead Sciences (GILD) stock fell by 2.73% last night, potentially due to mixed market sentiment and performance related to its recent investments and earnings, as exemplified by Ikena Oncology's earnings report and target price revision that indicates uncertainty in the biotech sector.

Gilead Sciences (GILD) stock rose by 2.65% last night, reflecting a strong performance with a 48.84% increase over the past year, likely due to positive market sentiment and confidence among long-term shareholders.

Gilead Sciences (GILD) stock rose by 2

Gilead Sciences (GILD) stock rose by 3.08% due to its strategic acquisition of a substantial position in Galapagos NV, which is involved in developing innovative biotechnological treatments, thereby increasing investor confidence.

Gilead Sciences (GILD) stock rose by 3

Gilead Sciences (GILD) stock rose 3.08% due to increased institutional investments, including a notable 10.4% stake increase by Private Advisor Group LLC and other hedge funds enhancing their positions, which reflects growing confidence in the company's performance and potential.

Gilead Sciences (GILD) stock rose 3

Gilead Sciences (GILD) stock saw a slight increase of 0.06% due to ongoing interest and investments by institutional investors in the biotechnology sector, specifically in companies like Arcellx, which Gilead has heavily invested in recently.

Gilead Sciences (GILD) stock saw a slight increase of 0

Gilead Sciences (GILD) stock fell by 0.53% due to concerns regarding its recent investment in Arcus Biosciences, which reported disappointing earnings and missed revenue expectations.

Gilead Sciences (GILD) stock fell by 0

HOOKIPA Pharma announced its intention to delist from Nasdaq and liquidate after agreeing to sell its assets to Gilead Sciences, which may have contributed to a 0.53% decline in Gilead's stock due to investor concerns about the implications of the asset sale on Gilead's future prospects and financial performance.

HOOKIPA Pharma announced its intention to delist from Nasdaq and liquidate after agreeing to sell it

Gilead Sciences (GILD) stock fell by 0.53% following a downgrade in Q2 2025 EPS estimates by Leerink Partners, reducing their forecast from $2.25 to $1.91 per share, which likely contributed to negative investor sentiment.

Gilead Sciences (NASDAQ: GILD) stock fell by 0.96% as several insiders sold shares, indicating potential lack of confidence, despite analysts raising earnings estimates and various upgrades in stock ratings.

Gilead Sciences (NASDAQ: GILD) stock fell by 0

Gilead Sciences (GILD) stock declined by 0.96% recently, potentially due to reactions to analyst downgrades and reduced price targets for related companies like Allogene Therapeutics, indicating broader concerns in the biotechnology sector.

Gilead Sciences (GILD) stock declined by 0

Gilead Sciences (NASDAQ: GILD) stock rose by 0.72% due to increased call options trading activity, with traders purchasing a significant number of call options, indicating bullish sentiment among investors.

Gilead Sciences (NASDAQ: GILD) stock rose by 0

Gilead Sciences (GILD) stock fell by 2.7% following Connecticut's recent law aimed at reducing state spending on weight-loss drugs, which could initiate broader efforts to control drug prices and introduce generic competitors to prominent GLP-1 medications. The stock drop is likely attributed to concerns about increased competition and pressure on drug prices in the pharmaceutical market, particularly as it relates to successful initiatives to lower costs that could impact Gilead's financial performance.

Gilead Sciences, Inc. (NASDAQ:GILD) saw its stock decline by 2.7% despite maintaining a "Buy" rating from analysts due to the promising potential of its new drug Yeztugo, which was approved for HIV prevention; the decline may be attributed to broader market volatility and competition from perceived better investment opportunities, particularly in AI stocks.

Gilead Sciences, Inc

Gilead Sciences (GILD) stock fell by 2.7% despite a maintained "Buy" rating and a $120 price target from analyst Courtney Breen, likely due to overall market fluctuations or investor reactions not directly related to the company’s fundamentals.

Gilead Sciences' stock (GILD) fell by 2.7% despite being recognized as a top healthcare stock by Goldman Sachs and recently announcing a partnership with the Global Fund to Fight Aids, Tuberculosis, and Malaria, possibly due to broader market trends or investor reactions to the agreement's implications.

Gilead Sciences' stock (GILD) fell by 2

Gilead Sciences (GILD) stock saw a 2.23% increase, reflecting its strong historical performance with an average annual return of 13.62% over the past 15 years and a current market capitalization of $139.43 billion. 

The stock likely rose due to positive investor sentiment or favorable market conditions, though specific reasons were not detailed in the article.

Gilead Sciences (GILD) stock saw a 2

Gilead Sciences (GILD) stock fell 4.28% amid a broader market decline influenced by concerns over new U.S. tariffs and mixed corporate earnings reports, particularly pressures in the financial and healthcare sectors where Gilead operates.

Gilead Sciences (GILD) stock fell 4

Gilead Sciences (GILD) stock fell by 3.2% amid a broader market decline influenced by escalating tariff threats from the Trump administration against Canada and other countries, which are raising concerns about potential impacts on trade and the pharmaceutical industry.

Gilead Sciences (GILD) stock fell by 3

Gilead Sciences (GILD) stock rose by 1.15% likely due to positive developments in Kyverna Therapeutics, in which Gilead acquired a significant stake, indicating growing confidence in the biopharmaceutical's potential in autoimmune disease therapies.

Gilead Sciences (GILD) stock rose by 1

Gilead Sciences, Inc. (NASDAQ:GILD) stock rose by 1.96% due to positive news regarding the ongoing development of its pediatric HIV clinical trial, which enhances its market position and investor confidence in the company's commitment to advancing antiretroviral therapies.

Gilead Sciences (GILD) stock fell by 0.64% due to concerns over Medicaid cuts, which could potentially reduce the company's revenue by 1% to 2% since about 25% of its revenue is linked to Medicaid, particularly from its HIV drug Biktarvy.

Gilead Sciences (GILD) stock saw a 0.22% uptick recently, likely influenced by analysts' positive assessments and a favorable shift in investor sentiment towards biotechnology stocks, including its stake in Agenus, which has garnered attention for potential growth in the immuno-oncology sector.

Gilead Sciences (GILD) stock saw a 0

Gilead Sciences (GILD) stock saw a slight increase of 0.18% due to positive movements in the market related to its acquisition of a significant stake in Arcus Biosciences, which is focused on developing cancer therapies, indicating growth potential in its investment.

Gilead Sciences (GILD) stock rose 1.6% due to increased investment from institutional investors, alongside favorable earnings results and positive ratings from research firms.

Gilead Sciences (GILD) stock rose 1

Gilead Sciences (GILD) stock declined by 1.18% likely due to a combination of market sentiment influenced by the poor performance and downgrades of related stocks, such as Allogene Therapeutics, which has faced negative analyst ratings and lower price targets.

Gilead Sciences (GILD) stock declined by 1

Gilead Sciences (GILD) stock rose by 0.95% due to its active trading volume and positive investor sentiment within the healthcare sector, which is experiencing notable interest through recent developments in medical treatments and regulatory approvals.

Gilead Sciences (GILD) stock dropped by 2.13% amidst an ongoing investigation into potential securities fraud and a recent FDA clinical hold on its HIV treatment trials due to safety concerns.

Gilead Sciences (GILD) stock dropped by 2

Gilead Sciences (GILD) stock fell by 2.13% amidst a backdrop of mixed analyst ratings and recent insider sales, indicating potential investor concern regarding its recent earnings report, where revenue fell short of expectations.

Gilead Sciences (GILD) stock fell by 2.13%, despite historically outperforming the market, due to broader market fluctuations and possible investor concerns about its future growth prospects.

Gilead Sciences (GILD) stock declined by 2.13% due to concerns over its recent investment in Arcus Biosciences, which reported disappointing earnings and significant revenue declines.

Gilead Sciences (GILD) stock was down 0.0% due to a recent FDA clinical hold on its HIV treatment trials, which raised concerns about the decrease in CD4+ T-cells, despite the company's overall strong performance and moderate valuation indicating potential for growth.

Gilead Sciences (GILD) stock was down 0

The article reports that Gilead Sciences, Inc. (GILD) is under investigation for potential securities fraud after the FDA placed a clinical hold on its HIV treatment trials due to safety concerns, which previously caused its stock to drop significantly. The Gilead Sciences (GILD) stock went down primarily due to the FDA's clinical hold on its investigational HIV treatments based on identified safety signals.

The article reports that Gilead Sciences, Inc

Gilead Sciences has received US approval for a new twice-a-year HIV prevention drug, Yeztugo, which is expected to significantly contribute to the company’s growth despite a recent 0.0% decline in its stock. The stock may have gone down due to market reactions to broader economic factors or investor profit-taking following recent gains, rather than the regulatory news surrounding the new drug.

Gilead Sciences has received US approval for a new twice-a-year HIV prevention drug, Yeztugo, which 

Gilead Sciences (GILD) stock dipped by 2.55% amid larger market movements and investor adjustments in the biotechnology sector, particularly following the recently reported disappointing earnings by Xilio Therapeutics, in which Gilead made an investment.

Gilead Sciences (GILD) stock dipped by 2

Gilead Sciences Inc. (NASDAQ:GILD) stock dropped by 2.55% following the FDA's decision to put a hold on studies of several HIV drugs due to safety concerns related to a decrease in CD4+ T-cells, raising uncertainties about the company's drug development pipeline.

Gilead Sciences Inc

Gilead Sciences (GILD) stock decreased by 2.55% due to concerns over the high level of institutional ownership, which may lead to increased volatility if multiple institutions change their views on the stock simultaneously.

Gilead Sciences (GILD) stock decreased by 2

Gilead Sciences (GILD) stock rose 0.77% due to significant investments in Arcus Biosciences, including a major stake purchase valued at $447.6 million, which indicates positive sentiment and potential growth prospects for the company.

Gilead Sciences (GILD) stock rose 0

Gilead Sciences (GILD) stock declined by 1.85% due to broader market influences and potential investor concerns, but the article primarily discusses institutional investors' activities related to Ikena Oncology, not directly Gilead Sciences.

Gilead Sciences (GILD) stock declined by 1.85% due to concerns surrounding the earnings estimates and performance of Tango Therapeutics, a company in which Gilead has invested, specifically after Tango missed its earnings expectations and reported lower revenue than anticipated.

Gilead Sciences (GILD) stock declined by -1.85% likely due to broader market trends or specific concerns affecting biopharmaceutical companies, as the article primarily discusses Nurix Therapeutics and its employee stock grants rather than specific news about Gilead.

Gilead Sciences (GILD) stock declined by -1

Gilead Sciences (NASDAQ:GILD) stock increased by 2.52% after Cantor Fitzgerald raised its FY2026 earnings per share estimate to $9.39 and maintained an "Overweight" rating with a $125 price target, reflecting positive outlook and analyst upgrades from various research firms.

Gilead Sciences (NASDAQ:GILD) stock increased by 2

Gilead Sciences (GILD) stock fell by 0.72%, potentially due to market reactions to broader investment movements, as the article discusses various hedge funds modifying their stakes in other biotech stocks, particularly Ikena Oncology.

Gilead Sciences (GILD) stock fell by 0.72% due to broader market trends affecting biotechnology stocks and possibly investor concerns regarding its recent investment in Kyverna Therapeutics, which, despite promising developments, has a challenging financial outlook.

Gilead Sciences (GILD) stock rose by 0.48% likely due to positive investment activity, as various institutional investors, including Gilead itself, increased their positions in Ikena Oncology, reflecting confidence in the company and its growth potential in the oncology market.

Gilead Sciences (GILD) stock rose by 0.48% due to increased institutional investment, including Gilead's own new stake in AlloVir, which indicates growing confidence in the potential of AlloVir's therapeutic developments.

Gilead Sciences (GILD) stock was up 0.48% due to increased investments and acquisitions in Tango Therapeutics, indicating positive market sentiment surrounding Gilead's strategic positioning in biotechnology.

Gilead Sciences (GILD) stock was up 0

The article discusses recent changes in holdings among institutional investors in Arcellx, Inc. (ACLX), with Gilead Sciences (GILD) notably acquiring a significant stake, which may have contributed to increased investor confidence and a subsequent 1.81% rise in Gilead Sciences stock.

The article discusses recent changes in holdings among institutional investors in Arcellx, Inc

Gilead Sciences (GILD) stock rose by 1.81% likely due to positive market sentiment stemming from the upcoming presentation of new clinical trial data from Nurix Therapeutics, which has collaborations with Gilead, enhancing investor confidence in their joint initiatives.

Gilead Sciences (GILD) stock rose 1.81% likely due to its new investment in Kyverna Therapeutics, alongside positive analyst ratings and interest from institutional investors, which may have boosted investor confidence.

Gilead Sciences (GILD) stock rose by 1.32% due to its participation in a financing round for Xilio Therapeutics, which raised $50 million, with the potential for additional funds through future warrant exercises, suggesting confidence in the growing biotech sector and the potential for lucrative investments in innovative cancer therapies.

Gilead Sciences (GILD) stock increased by 1.32% due to its strategic investment in AlloVir, Inc. during the fourth quarter, indicating investor confidence in potential future gains from its new position in the emerging biopharmaceutical space.

Gilead Sciences (GILD) stock increased by 1

Gilead Sciences (GILD) stock rose by 1.32%, influenced by favorable updates regarding Allogene Therapeutics' anticipated earnings, which reflect positive sentiment in the biotech sector and potential investor confidence in related companies.

Gilead Sciences (GILD) stock rose by 1.32% likely due to increased institutional investment in related companies like Allogene Therapeutics, developments from research analysts maintaining positive ratings, and overall positive market sentiment towards biotech stocks.

Gilead Sciences (GILD) stock declined by 0.28% likely due to market sentiment surrounding biotechnology stocks, alongside institutional trading activities and recent earnings reports that may not have met investor expectations.

Gilead Sciences (GILD) stock rose by 0.39% primarily due to its strategic investments in Kyverna Therapeutics and overall positive analyst ratings and upgrades for the latter, indicating increased investor confidence.

Gilead Sciences (GILD) stock increased by 0.39% likely due to positive institutional investment trends, including Gilead's own acquisition of a significant stake in Agenus, which may reflect confidence in the biotechnology sector's growth potential.

Gilead Sciences (GILD) stock increased by 0

The article primarily focuses on institutional investments in Kronos Bio, Inc. (KRON), noting Gilead Sciences, Inc. (GILD) recently purchased a stake in the company; however, it does not provide specific reasons for Gilead's stock increase of 0.39%. The increase in Gilead's stock could be attributed to broader market trends, positive investor sentiment, or developments in the biotechnology sector, including its potential strategic investments in promising companies like Kronos Bio.

The article primarily focuses on institutional investments in Kronos Bio, Inc

The article reports that Gilead Sciences (GILD) stock rose by 0.39%, following significant institutional investments in Kyverna Therapeutics, which may reflect growing investor confidence and interest in biotech sectors, particularly those involved in innovative therapies.

The article reports that Gilead Sciences (GILD) stock rose by 0

Gilead Sciences (GILD) stock fell by 1.06% last night despite its impressive long-term market performance, likely due to broader market fluctuations or specific investor concerns impacting short-term trading sentiment.

Gilead Sciences (GILD) stock fell by 1

Gilead Sciences (GILD) stock fell by 1.06%, potentially influenced by broader market trends and company-specific developments, such as the competitive landscape and uncertainty surrounding ongoing clinical trials, including those of related companies like Protara Therapeutics that may attract investor attention.

The article discusses a prospective multicenter observational study, named GRIPonMASH, aimed at improving the identification and screening of patients at risk for metabolic dysfunction-associated steatotic liver disease (MASLD) in Europe, while Gilead Sciences (GILD) stock recently dropped by -0.93% due to broader market pressures or concerns regarding the implications of new treatments in the pharmaceutical landscape.

The article discusses a prospective multicenter observational study, named GRIPonMASH, aimed at impr

Gilead Sciences (GILD) stock rose by 2.46% due to positive investment developments surrounding Kyverna Therapeutics, in which Gilead recently invested significantly, coinciding with upgrades in the ratings and price targets for Kyverna's stock by various analysts.

Gilead Sciences (NASDAQ:GILD) stock rose 0.59% following the disclosure of an insider sale of shares and positive earnings results that beat analyst expectations, as well as recent upgrades in price targets by various analysts, indicating continued investor confidence.

Gilead Sciences (NASDAQ:GILD) stock rose 0

Gilead Sciences (GILD) stock declined by 0.91% due to broader market pressures and potentially negative sentiment following a disappointing earnings report from Arcellx, Inc. (ACLX), in which Gilead had recently increased its holdings.

Gilead Sciences (GILD) stock fell 0.91% due to a slight decline in quarterly revenue compared to analyst expectations, despite a positive earnings per share report.

Gilead Sciences (GILD) stock fell 0

Gilead Sciences (GILD) stock rose by 2.78% likely due to positive earnings estimates and analyst upgrades for Agenus Inc. (NASDAQ: AGEN), which Gilead recently invested in, signaling growing confidence in the biotechnology sector's recovery and potential profitability.

The article discusses Nurix Therapeutics, Inc. granting stock options and restricted stock unit awards to new employees as part of their equity inducement plan, indicating a focus on recruiting talent to advance their drug development efforts, but does not directly explain the increase in Gilead Sciences (GILD) stock, which may be influenced by broader market trends, investor sentiment, or specific developments related to Gilead's collaborations with Nurix, particularly in targeted protein degradation therapies.

The article discusses Nurix Therapeutics, Inc

Gilead Sciences (GILD) stock rose by 2.15% due to positive market sentiment and potential investor confidence linked to developments in related biotechnology sectors, notably with Allogene Therapeutics experiencing mixed analyst ratings which may impact broader investor interest in similar stocks.

Gilead Sciences (GILD) stock fell by 3.01% likely due to investor concerns stemming from the announcement of Nurix Therapeutics' upcoming presentations of clinical trial data for their investigational BTK degrader, bexobrutideg, suggesting potential competition in the oncology market.

Gilead Sciences (GILD) stock fell by 0.84% last night amid broader market fluctuations and ongoing concerns within the biotechnology sector regarding competition and product pipelines, as exemplified by comparisons with companies like Lexaria Bioscience and GlobeImmune.

Gilead Sciences (GILD) stock declined by 2.0% recently, possibly due to mixed sentiment from analysts and ongoing performance concerns.

Gilead Sciences (GILD) stock increased by 3.07% last night, likely due to the announcement of a quarterly dividend of $0.79 per share for the second quarter of 2025, which reflects positively on the company's financial health and commitment to returning value to shareholders.

Gilead Sciences (GILD) stock increased by 3

Gilead Sciences (GILD) stock rose 3.07% following a positive earnings announcement that exceeded analysts’ estimates, coupled with multiple upgrades in price targets and ratings from various research firms, indicating growing analyst confidence in the company's prospects.

Gilead Sciences (GILD) stock rose by 3.07% following an increase in FY2025 earnings per share estimates from Cantor Fitzgerald, which forecasted earnings of $7.96 per share, and positive ratings upgrades from multiple analysts, boosting overall investor confidence in the company's financial outlook.

Gilead Sciences (GILD) stock rose 3.07% last night, likely due to positive market sentiment around its collaborations and strategic partnerships in the oncology sector, including initiatives with IDEAYA Biosciences and the promising pipeline of product candidates under development.

Gilead Sciences (GILD) stock fell by 2.81% due to missed first-quarter revenue estimates driven by declining sales of its COVID-19 and cancer drugs, despite seeing gains in HIV treatment demand.

Gilead Sciences (GILD) stock fell by 2.81% due to weak sales of its COVID-19 and cancer treatments, alongside a reduced profit outlook for 2025, despite better-than-expected earnings per share.

Gilead Sciences (GILD) stock fell by 2.81% following a quarterly earnings report that exceeded earnings per share (EPS) expectations but fell short on revenue estimates, leading to investor concern despite an overall optimistic earnings forecast by analysts.

Gilead Sciences (GILD) stock decreased by 2.81% following the release of its quarterly earnings, which beat EPS expectations but missed revenue forecasts, contributing to investor concerns.

Gilead Sciences (GILD) stock declined by 2.81% due to risks associated with drug development and the competitive landscape highlighted at the American Association for Cancer Research (AACR) meeting, particularly in relation to the advancements and potential efficacy of Nurix Therapeutics' new cancer therapies.

Gilead Sciences (GILD) stock declined by 0.22% following the release of its first-quarter earnings, which surpassed analyst expectations with earnings of $1.81 per share. The decrease in stock price could be attributed to broader market trends or investor sentiment, despite the positive earnings report.

Gilead Sciences (GILD) stock was down 0.22% due to analysts favoring 4D Molecular Therapeutics over Gilead, citing a higher potential upside for 4D, which may reflect concerns about Gilead's competitive position and stock performance.

Gilead Sciences (GILD) stock was down 0.22% amidst a generally positive outlook, with analysts providing a consensus recommendation of "Moderate Buy" and several raising their price targets for the stock, but it possibly declined due to recent insider stock sales and market fluctuations.

Gilead Sciences' stock dropped by 0.22% after two of its key drugs failed to meet sales expectations, which could negatively impact investor sentiment.

Gilead Sciences' stock dropped by 0

Gilead Sciences (GILD) stock has recently risen by 1.41% to $107.00, reflecting a significant annual gain of 62.98%, despite a slight decline over the past month, likely due to positive investor sentiment or upcoming product developments.

Gilead Sciences (GILD) stock has recently risen by 1

Gilead Sciences (GILD) stock rose by 0.82% as the company is set to announce its Q1 2025 earnings, which are expected to exceed analyst estimates, and due to positive analyst ratings, including increased price targets from several investment firms.

Gilead Sciences (GILD) stock experienced a slight decline of -0.2% largely due to significant insider selling and a 25.2% reduction in holdings by XTX Topco Ltd, which may have affected investor confidence.

Gilead Sciences (GILD) stock experienced a slight decline of -0

Gilead Sciences (GILD) stock declined by 0.32%, which may be attributed to broader market trends affecting biotech stocks and competition from other companies like Exelixis and Agenus, which show more favorable potential from analyst ratings and price targets.

Gilead Sciences (GILD) stock fell by 0.76%, potentially due to investor reactions to broader market conditions or concerns regarding its competitive position among undervalued stocks, as indicated in a recent article analyzing its standing against quality stocks.

Gilead Sciences (GILD) stock rose by 2.2% due to positive market sentiment likely fueled by strategic collaborations and advancements in innovative drug development, exemplified by Nurix Therapeutics' announcements which indicate potential benefits from their ongoing partnership.

Gilead Sciences (GILD) stock rose by 2.0% due to strong fourth-quarter earnings growth and positive news regarding its HIV prevention drug Lenacapavir, which is under review for U.S. approval, along with favorable reception of its cirrhosis treatment, Livdelzi.

Gilead Sciences (GILD) stock rose by 2.0% last night, potentially due to strong interest and confidence in its strategic collaborations, such as with Tango Therapeutics, which enhance its drug development pipeline in oncology.

Gilead Sciences (GILD) stock was up 2.0% recently, likely due to positive market sentiment surrounding its strategic collaborations and ongoing developments in its therapeutic areas, which may signal potential growth and solid returns for investors.

Gilead Sciences (GILD) stock was up 2

Gilead Sciences (GILD) stock rose 2.0% due to positive market sentiment and potential investment interest, particularly involving new stakes purchased by hedge funds in Arcus Biosciences, which may enhance collaborative opportunities and strategic positioning in the biopharmaceutical sector.

Gilead Sciences (GILD) stock rose 2

Gilead Sciences (GILD) stock declined by 2.21% due to market reactions and possibly investor concerns following Nurix Therapeutics' recent financial report and updates on its drug development pipeline, which may have affected sentiment around Gilead's partnership and its own progress in the biopharmaceutical market.

Gilead Sciences (GILD) stock fell by 2.21% following a recent quarterly earnings announcement that exceeded expectations but may have been influenced by insider selling and broader market conditions.

The article highlights that Gilead Sciences (NASDAQ:GILD) stock rose 0.45% due to its strong performance in a thriving sector and its attractive valuation relative to peers, as noted by Rob Sechan and supported by JP Morgan analysis.

The article highlights that Gilead Sciences (NASDAQ:GILD) stock rose 0

The article discusses various large-cap stocks, including Gilead Sciences (GILD), which recently saw a 0.55% increase, likely due to overall investor confidence in U.S. stocks despite uncertainty surrounding tariffs and economic conditions. The rise may also be attributed to strong performance in sectors like healthcare, where Gilead Sciences is involved.

The article discusses various large-cap stocks, including Gilead Sciences (GILD), which recently saw

Gilead Sciences (GILD) stock decreased by 0.69% likely due to the overall negative sentiment surrounding Leap Therapeutics, in which Gilead holds a significant interest, following a downgrade in the company's earnings estimates by HC Wainwright and other analysts.

Gilead Sciences (GILD) stock decreased by 0

Gilead Sciences (GILD) stock rose 1.73% last night, following its historical outperformance in the market with an average annual return of 13.4% over the past 20 years. 

The stock's increase may be attributed to investor confidence in its long-term growth potential, supported by solid financial performance and market position.

Gilead Sciences (GILD) stock rose by 1.08% likely due to positive developments or investor sentiment surrounding related biopharmaceutical advancements, as highlighted by Nurix Therapeutics' upcoming presentations at the AACR 2025 Annual Meeting, which may have implications for drug partnerships and market confidence.

Gilead Sciences (GILD) stock rose by 1.14% due to positive market sentiment surrounding the biotechnology sector, particularly following favorable quarterly earnings reports and analyst upgrades for related companies like Allogene Therapeutics.

Gilead Sciences' stock (GILD) rose by 1.14% due to its recognition among the top pharmaceutical stocks to watch, indicating increased investor interest and trading activity possibly fueled by its portfolio of innovative therapies for unmet medical needs.

Gilead Sciences' stock (GILD) rose by 1

Gilead Sciences (GILD) stock declined by 1.53% likely due to concerns over the progress and outcomes of its collaboration with Assembly Biosciences, which includes investigational therapeutics that have not yet demonstrated safety and efficacy.

Gilead Sciences (GILD) stock declined by 1.53% due to competitive pressures in the oncology small molecule drugs market, where strategic investments by rival companies, particularly in new cancer therapies, signal strong competitive dynamics that may affect Gilead's market position and growth prospects.

Gilead Sciences (GILD) stock fell by 1.53% due to broader market trends and potential investor reactions to recent performance metrics and analyst estimates related to its portfolio, including news from associated companies like Arcus Biosciences.

Gilead Sciences (GILD) stock fell 2.52% to $107.45 in premarket trading due to a report that the US Health and Human Services Department may cut federal funding for HIV prevention, which could negatively impact the company's business as it specializes in HIV treatments.

Gilead Sciences (GILD) stock fell 2

Gilead Sciences (GILD) stock declined by 2.47% in premarket trading due to reports that the Health and Human Services Department may significantly cut federal funding for domestic HIV programs.

Gilead Sciences' stock fell by 2.47% due to reports that the Health and Human Services (HHS) department may reduce federal funding for HIV prevention programs, which are crucial for the company's revenue.

Gilead Sciences' stock fell by 2

Gilead Sciences (GILD) stock fell by 2.47% due to a variety of potential factors affecting pharmaceutical stocks, such as market fluctuations, investor sentiment, or reactions to company-specific news, though specific reasons for GILD's decline were not detailed in the article.

Gilead Sciences (GILD) stock fell by 1.81% due to a consensus price target that indicates a potential downside, suggesting that analysts anticipate challenges ahead for the company's stock performance.

Gilead Sciences (GILD) stock fell by 1.69% likely due to broader market pressures or specific concerns related to its business units, as the article primarily discusses Nurix Therapeutics and its grant of inducement awards but does not provide direct reasons for Gilead's stock decline.

Gilead Sciences (GILD) stock experienced a decline of 1.69% alongside a drop in Tango Therapeutics' earnings projections, indicating broader market sentiment may have been affected by concerns about performance in the biotechnology sector.

Gilead Sciences (GILD) stock experienced a decline of 1

Gilead Sciences (GILD) stock dropped by 0.56% despite upward adjustments to its price targets by several investment firms, indicating potential investor concerns might be weighing on the stock's short-term performance.

Gilead Sciences (GILD) stock dropped by 0

Gilead Sciences (GILD) stock fell by 2.37% due to concerns surrounding developments in the competitive landscape of the biotechnology sector, particularly highlighted by Xilio Therapeutics' promising updates on its tumor-activated immuno-oncology therapies, which may threaten Gilead's market position.

Gilead Sciences (GILD) stock decreased by 0.17% last night, possibly due to a general adverse market sentiment or sector-specific issues, as the article primarily focuses on comparing other biotech companies, Cortexyme and Agenus, without specifying Gilead's specific challenges.

Gilead Sciences (GILD) stock rose by 1.18% likely due to its acquisition of a new stake in Barinthus Biotherapeutics, indicating confidence in potential growth from this clinical-stage biopharmaceutical company’s immunotherapeutic candidates.

Gilead Sciences (GILD) stock rose by 1.18% following an upgrade in its target price from $120 to $140 by Wells Fargo, indicating a potential upside and reinforcing the biopharmaceutical company's overall positive outlook among analysts.

Gilead Sciences (GILD) stock increased by 0.52%, reflecting its consistent outperformance in the market with an average annual return of 13.79% over the past 20 years, driven by strong market fundamentals and investor confidence.

Gilead Sciences (GILD) stock rose by 0.61% following an increase in its price target by Oppenheimer, from $115.00 to $132.00, along with several other analysts upgrading their ratings, which indicates strong optimism for the company's future performance.

Gilead Sciences (GILD) stock was down 1.08% likely due to overall market conditions affecting biotech stocks and disappointing financial performance of companies like Arcellx, which may have impacted investor sentiment in the sector.

Gilead Sciences (GILD) stock was down 1

Gilead Sciences (GILD) stock declined by 1.08%, potentially due to market fluctuations or investor sentiment affecting medical stocks, as they were highlighted for their trading volumes alongside other major healthcare companies on the same day.

Gilead Sciences (GILD) stock rose by 1.39% due to positive market sentiments following new reports on their products and potential advancements in their treatments, boosting investor confidence.

Headline	Summary	Source
Gilead Sciences (GILD) stock was down by 2	Gilead Sciences (GILD) stock was down by 2.15% due to competitive pressure from other biotech firms such as Assembly Biosciences and Targeted Medical Pharma, which may have raised concerns among investors about Gilead's market position and growth potential.	ETF Daily News
Gilead Sciences (GILD) stock declined by 2	Gilead Sciences (GILD) stock declined by 2.15% as it reacted negatively to broader market trends and uncertainty surrounding future earnings, despite significant investments from Orchestra BioMed and Medtronic aimed at advancing their cardiology programs, indicating a lack of investor confidence in Gilead's immediate outlook.	Globenewswire
Gilead Sciences (GILD) stock fell by 2	Gilead Sciences (GILD) stock fell by 2.15% due to broader market trends and investor sentiment potentially influenced by recent news, including significant IPOs like Figma's, which may be diverting focus and capital away from established biotech stocks like Gilead.	Businessinsider

GILD

Latest News & Analysis